Key Highlights
- SCHOTT Pharma to open its first U.S. facility for prefillable polymer syringes, vital for mRNA medications, and glass syringes for GLP-1 therapies.
- The $371 million investment will enhance the U.S. supply chain, ensuring faster delivery and pandemic preparedness, with operations starting in 2027.
- This move is part of SCHOTT’s strategic plan to triple its syringe contribution to the U.S. market by 2030, backed by $21 million in state and local incentives.
Source: Business Wire
Notable Quotes
- “As drug manufacturers develop and expand the use of mRNA, GLP-1, and other biologic therapies that require precise drug stability and storage properties, SCHOTT Pharma will be able to fill those orders quickly and efficiently here in the U.S.,” – Andreas Reisse, CEO at SCHOTT Pharma
- “Wilson County stood out in a nationwide search for a number of reasons, particularly for its favorable pool of local talent and its proximity to the Research Triangle area,” – Christopher Cassidy, President at SCHOTT North America
- “SCHOTT Pharma’s $371 million capital investment and 401 high-wage jobs will strengthen our local economy. We look forward to a long and successful future for them here in Wilson,” – Senator Buck Newton, North Carolina
SoHC's Take
SCHOTT Pharma’s decision to establish its newest manufacturing facility in Wilson, North Carolina, is a strategic move that reinforces the importance of localized production capabilities in the pharmaceutical supply chain. This investment not only underlines the critical nature of maintaining a robust infrastructure for the production of essential medical supplies but also highlights the growing need for advanced drug delivery systems amidst the increasing complexity of biologic therapies. The expansion is poised to significantly enhance SCHOTT Pharma’s operational efficiency and responsiveness to market demands, ensuring the company remains at the forefront of innovation in drug containment and delivery solutions. This strategic development is emblematic of the broader trends in the pharmaceutical industry towards enhancing supply chain resilience, promoting sustainable practices, and supporting regional economic development.
